comprehensive -WSS

comprehensive

author：comprehensive 2025-09-06 04:51:42 - browse：5

Business standing in the middle of a maze near a bag with a dollar sign on it. -- biotech coverage from STAT — Adobe

Over the last year or two, something curious has started occurring in the conference rooms and private Zoom meetings of biotech venture capitalists.

Representatives from pension funds, college endowments, family offices, and other organizations with money to invest have become bolder in their requests, according to interviews with a host of VCs. They’re pushing not only for advantageous terms in a VC firm’s latest fund, but in some cases, have angled for equity in the firm itself. These types of conditions aren’t unheard of, but have become more frequent as venture capitalists have a harder time raising funds, and as outside investors feel empowered to ask for more bang for their buck.

“A lot is changing in venture fundraising right now,” said Nan Li, co-founder and managing partner of Dimension, which launched last January. Outside investors tried to ask for a piece of Dimension, but the new firm had more than enough interest in its first fund and was able to turn down those proposals. Two other young VC firms told STAT they’ve fielded similar requests, and one investment group reported that it had managed to negotiate an equity stake in a VC firm.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： FDA panel signals lack of confidence in Amgen cancer drug data

WSS

California store owner shot dead in dispute over displaying Pride flag: Police

Wegovy improves function in certain heart failure patients

A virus, fished out of a lake, may have saved a man’s life

Analysis of telehealth claims data suggest service duplication

Can U.S. cancer drug shortages be fixed?

What to expect at HLTH 2023, the health care industry conference

hotspot

comprehensive

focus

Anesthesiologist group: stop taking Ozempic before surgery

FDA advisory panel to debate high blood pressure devices

Medicare proposal to cover medical devices draws a mixed reaction

FDA advisory panel to debate high blood pressure devices

After affirmative action ruling, medical educators look to 'holistic review'

How the drug

Tori Bowie and the unacceptable rates of Black maternal death

Readout Newsletter: Biotech news, including Moderna's Covid vaccine

Bright Health sells Medicare Advantage business to Molina

How to make over

hotspot

3 questions for the future of Biden's cancer moonshot

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

Physician executives need more than on

VC firm General Catalyst wants to buy a health system

Liquid biopsy for lung cancer is launched by Delfi

focus

knowledge

hotspot

focus